Skip to content

Erik D. Wiklund

Erik D. Wiklund

Company: Targovax

Job title: Chief Business Officer


Erik trained as a scientist specializing in cancer epigenetics research, and holds a PhD in molecular biology. After completing a postdoctoral fellowship, he transitioned to management consulting and joined the Pharma and Healthcare practice of McKinsey & Company. For the past 5 years he has held several positions in Norwegian biotech companies, including at Alegta, which developed and launched Xofigo in 2014. He joined Targovax as CFO in 2017, and transitioned into the CBO position in 2018.


Vaccination Against Mutant RAS in Resected Pancreatic Cancer 3:15 pm

Review of Targovax’s TG peptide vaccine program, which targets all codon 12 and 13 RAS mutations in parallel Results from the recently completed 32-patient TG01 mutRAS vaccination trial in resected pancreatic cancer to be presented Data shows robust levels of mutant RAS immune activation and a signal of clinical efficacy  Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.